These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Broadly neutralizing antibodies and vaccine design against HIV-1 infection. Wang Q; Zhang L Front Med; 2020 Feb; 14(1):30-42. PubMed ID: 31858368 [TBL] [Abstract][Full Text] [Related]
3. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses. Ringel O; Vieillard V; Debré P; Eichler J; Büning H; Dietrich U Viruses; 2018 Apr; 10(4):. PubMed ID: 29662026 [TBL] [Abstract][Full Text] [Related]
4. Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome. Hurwitz JL; Bonsignori M Viral Immunol; 2018 Mar; 31(2):124-132. PubMed ID: 29315059 [TBL] [Abstract][Full Text] [Related]
5. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M J Virol; 2017 May; 91(9):. PubMed ID: 28179536 [TBL] [Abstract][Full Text] [Related]
6. Natural infection as a blueprint for rational HIV vaccine design. van Haaren MM; van den Kerkhof TL; van Gils MJ Hum Vaccin Immunother; 2017 Jan; 13(1):229-236. PubMed ID: 27649455 [TBL] [Abstract][Full Text] [Related]
7. HIV-1 vaccines: challenges and new perspectives. Excler JL; Robb ML; Kim JH Hum Vaccin Immunother; 2014; 10(6):1734-46. PubMed ID: 24637946 [TBL] [Abstract][Full Text] [Related]
8. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y J Virol; 2017 May; 91(9):. PubMed ID: 28202751 [TBL] [Abstract][Full Text] [Related]
9. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans. Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165 [TBL] [Abstract][Full Text] [Related]
10. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development. O'Connell RJ; Kim JH; Excler JL Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695 [TBL] [Abstract][Full Text] [Related]
11. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? Subbaraman H; Schanz M; Trkola A Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627 [TBL] [Abstract][Full Text] [Related]
12. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585 [TBL] [Abstract][Full Text] [Related]
14. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies. Ahmed Y; Tian M; Gao Y AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278 [TBL] [Abstract][Full Text] [Related]
15. Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis. Dai K; He L; Khan SN; O'Dell S; McKee K; Tran K; Li Y; Sundling C; Morris CD; Mascola JR; Karlsson Hedestam GB; Wyatt RT; Zhu J mBio; 2015 Nov; 6(6):e01375-15. PubMed ID: 26530382 [TBL] [Abstract][Full Text] [Related]
16. New approaches to HIV vaccine development. Haynes BF Curr Opin Immunol; 2015 Aug; 35():39-47. PubMed ID: 26056742 [TBL] [Abstract][Full Text] [Related]
17. Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. Pollara J; Jones DI; Huffman T; Edwards RW; Dennis M; Li SH; Jha S; Goodman D; Kumar A; LaBranche CC; Montefiori DC; Fouda GG; Hope TJ; Tomaras GD; Staats HF; Ferrari G; Permar SR J Virol; 2019 May; 93(10):. PubMed ID: 30842326 [TBL] [Abstract][Full Text] [Related]
18. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design. Sadanand S; Suscovich TJ; Alter G Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674 [TBL] [Abstract][Full Text] [Related]
19. Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development? Medina-Ramírez M; Sanders RW; Klasse PJ Expert Rev Vaccines; 2014 Apr; 13(4):449-52. PubMed ID: 24606603 [TBL] [Abstract][Full Text] [Related]
20. HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component. Yang L; Song Y; Li X; Huang X; Liu J; Ding H; Zhu P; Zhou P J Virol; 2012 Jul; 86(14):7662-76. PubMed ID: 22553333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]